amfAR 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...2021»
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Leronlimab Works. (Twitter) -  Mar 26, 2022   
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Trial completion date, Trial primary completion date, Metastases:  Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC (clinicaltrials.gov) -  Mar 20, 2022   
    P1/2,  N=48, Active, not recruiting, 
    No abstract available Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Jul 2022
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    #Leronlimab (Twitter) -  Mar 11, 2022   
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Journal:  CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. (Pubmed Central) -  Mar 5, 2022   
    Finally, we extended these results to Leronlimab-treated humans and found that weekly 700 mg Leronlimab led to complete CCR5 RO on peripheral blood CD4+ T cells and a statistically significant increase in CCR5+CD4+ T cells in peripheral blood. Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation (clinicaltrials.gov) -  Jan 28, 2022   
    P2,  N=12, Terminated, 
    Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes. N=60 --> 12 | Trial completion date: Dec 2019 --> Sep 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Apr 2021; Study terminated due to lack of enrolment..